| General Information | |
|---|---|
| ZINC ID | ZINC000062225251 |
| Molecular Weight (Da) | 386 |
| SMILES | CCCCCC1=NN(C(=O)Nc2cccc3ccccc23)C[C@H]1c1ccccc1 |
| Molecular Formula | C25N3O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 119.234 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 29 |
| LogP | 6.334 |
| Activity (Ki) in nM | 36.308 |
| Polar Surface Area (PSA) | 44.7 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.21 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 16 |
| Fraction csp3 | 0.28 |
| Ilogp | 4.24 |
| Xlogp3 | 5.76 |
| Wlogp | 5.46 |
| Mlogp | 4.77 |
| Silicos-it log p | 5.32 |
| Consensus log p | 5.11 |
| Esol log s | -5.74 |
| Esol solubility (mg/ml) | 0.000703 |
| Esol solubility (mol/l) | 0.00000182 |
| Esol class | Moderately |
| Ali log s | -6.47 |
| Ali solubility (mg/ml) | 0.000132 |
| Ali solubility (mol/l) | 0.00000034 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.5 |
| Silicos-it solubility (mg/ml) | 0.00000122 |
| Silicos-it solubility (mol/l) | 3.16E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.56 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 4.2 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.467 |
| Logd | 4.9 |
| Logp | 6.355 |
| F (20%) | 0.423 |
| F (30%) | 0.828 |
| Mdck | 2.03E-05 |
| Ppb | 0.9749 |
| Vdss | 0.945 |
| Fu | 0.0283 |
| Cyp1a2-inh | 0.45 |
| Cyp1a2-sub | 0.933 |
| Cyp2c19-inh | 0.944 |
| Cyp2c19-sub | 0.867 |
| Cl | 2.151 |
| T12 | 0.071 |
| H-ht | 0.79 |
| Dili | 0.981 |
| Roa | 0.645 |
| Fdamdd | 0.062 |
| Skinsen | 0.3 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.898 |
| Bcf | 1.965 |
| Igc50 | 4.899 |
| Lc50 | 5.963 |
| Lc50dm | 5.526 |
| Nr-ar | 0.051 |
| Nr-ar-lbd | 0.006 |
| Nr-ahr | 0.939 |
| Nr-aromatase | 0.613 |
| Nr-er | 0.851 |
| Nr-er-lbd | 0.193 |
| Nr-ppar-gamma | 0.946 |
| Sr-are | 0.502 |
| Sr-atad5 | 0.025 |
| Sr-hse | 0.612 |
| Sr-mmp | 0.937 |
| Sr-p53 | 0.739 |
| Vol | 422.146 |
| Dense | 0.913 |
| Flex | 0.348 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 2 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 4 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 2 |
| Qed | 0.49 |
| Synth | 2.8 |
| Fsp3 | 0.28 |
| Mce-18 | 62.5 |
| Natural product-likeness | -0.567 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |